Abstract
Background: Multiple sclerosis is an autoimmune chronic inflammatory disease of the central nervous system that can lead to some serious disabilities. Despite using various immunomodulatory and anti-inflammatory drugs that have therapeutic effects, they cannot reduce its progression completely and have some unwanted side effects too. The immunomodulatory and anti-inflammatory effects of the β-D-Mannuronic acid (M2000) have been proven in several surveys, and the present research was designed to determine its toxicity and therapeutic effects in MS patients.
Methods: This study was performed on 15 MS patients who took 25 mg/kg/day the oral form of the β-D-Mannuronic acid for six months, and 15 healthy people as a control group. Serum levels of Urea, Creatinine, GGT, Vitamin D3, Uric acid, and Anti-Phospholipids were compared to evaluate the therapeutic and possible toxic effects of this drug after this period. Results: Non- toxic effects through the study of urea, creatinine, GGT, and non-significant changes in uric acid and anti-Phospholipids levels, besides a significant rise in vitamin, D3 levels in the M2000 treated cases were found. Conclusions: Our results suggested that β-D-Mannuronic acid is a safe drug and has no toxicity when administered orally and also has some therapeutic effects in MS patients.Keywords: Mannuronic acid, M2000, multiple sclerosis, drug safety, toxicology, biochemical markers, NSAIDs.
Graphical Abstract
Current Drug Discovery Technologies
Title:Assessment of Biochemical Determinants in Multiple Sclerosis Patients Following the Oral Administration of β-D-Mannuronic Acid (M2000)
Volume: 18 Issue: 5
Author(s): Mohamad Reza Nikouei Moghaddam, Monireh Movahedi, Maryam Bananej, Soheil Najafi, Nahid Beladi Moghadam, Payam Saadat, Fariba Mokhtarian and Abbas Mirshafiey*
Affiliation:
- Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran,Iran
Keywords: Mannuronic acid, M2000, multiple sclerosis, drug safety, toxicology, biochemical markers, NSAIDs.
Abstract: Background: Multiple sclerosis is an autoimmune chronic inflammatory disease of the central nervous system that can lead to some serious disabilities. Despite using various immunomodulatory and anti-inflammatory drugs that have therapeutic effects, they cannot reduce its progression completely and have some unwanted side effects too. The immunomodulatory and anti-inflammatory effects of the β-D-Mannuronic acid (M2000) have been proven in several surveys, and the present research was designed to determine its toxicity and therapeutic effects in MS patients.
Methods: This study was performed on 15 MS patients who took 25 mg/kg/day the oral form of the β-D-Mannuronic acid for six months, and 15 healthy people as a control group. Serum levels of Urea, Creatinine, GGT, Vitamin D3, Uric acid, and Anti-Phospholipids were compared to evaluate the therapeutic and possible toxic effects of this drug after this period. Results: Non- toxic effects through the study of urea, creatinine, GGT, and non-significant changes in uric acid and anti-Phospholipids levels, besides a significant rise in vitamin, D3 levels in the M2000 treated cases were found. Conclusions: Our results suggested that β-D-Mannuronic acid is a safe drug and has no toxicity when administered orally and also has some therapeutic effects in MS patients.Export Options
About this article
Cite this article as:
Nikouei Moghaddam Mohamad Reza , Movahedi Monireh , Bananej Maryam, Najafi Soheil, Moghadam Beladi Nahid , Saadat Payam , Mokhtarian Fariba and Mirshafiey Abbas *, Assessment of Biochemical Determinants in Multiple Sclerosis Patients Following the Oral Administration of β-D-Mannuronic Acid (M2000), Current Drug Discovery Technologies 2021; 18 (5) : e17092020186049 . https://dx.doi.org/10.2174/1570163817999200918104333
DOI https://dx.doi.org/10.2174/1570163817999200918104333 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
IgA/IgM Responses to Gram-Negative Bacteria are not Associated with Perinatal Depression, but with Physio-somatic Symptoms and Activation of the Tryptophan Catabolite Pathway at the End of Term and Postnatal Anxiety
CNS & Neurological Disorders - Drug Targets Growth Restriction: Etiology, Maternal and Neonatal Outcome. A Review
Current Women`s Health Reviews Chinese Character Voice Processing of the Bilateral Inferior Parietal Lobule of Literate Compared with Illiterate Subjects: An fMRI Study
Neuroscience and Biomedical Engineering (Discontinued) MIIP, a Cytoskeleton Regulator that Blocks Cell Migration and Invasion, Delays Mitosis, and Suppresses Tumorogenesis
Current Protein & Peptide Science Design and Development of a Novel Supportive Care Product for the Treatment of Sialorrhea in Parkinson’s Disease
Current Topics in Medicinal Chemistry Biomedical Devices for Pathogen Detection Using Microfluidic Chips
Current Proteomics Adenosine A1 Receptor: Analysis of the Potential Therapeutic Effects Obtained by its Activation in the Central Nervous System
Current Medicinal Chemistry Postmenopausal Osteoporosis and Aerobic Exercise: A Review of the Literature
Current Rheumatology Reviews Balancing Antioxidant, Hypolipidemic and Anti-inflammatory Activity in a Single Agent: The Example of 2-Hydroxy-2-Substituted Morpholine, 1,4-Benzoxazine and 1,4-Benzothiazine Derivatives as a Rational Therapeutic Approach against Atherosclerosis
Current Medicinal Chemistry Impact of Collateral Status on Neuroprotective Effect of Cyclosporine A in Acute Ischemic Stroke
Current Neurovascular Research Stereospecific Determination of Sertraline and its Impurities in Bulk Drug Using Cyclodextrins as a Chiral Selector
Current Pharmaceutical Analysis Psychosocial Stress, Emotions and Cytokine-Related Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Finding Simple Rules for Discriminating Folding Rate Change upon Single Mutation by Statistical and Learning Methods
Protein & Peptide Letters Use of Terpenoids as Natural Flavouring Compounds in Food Industry
Recent Patents on Food, Nutrition & Agriculture A Review of Recent Patents on the ASICs as a Key Drug Target
Recent Patents on Biotechnology Stability of Drugs of Abuse in Urine Samples at Room Temperature by Use of a Salts Mixture
Current Pharmaceutical Biotechnology Diagnostic Cardiac Catheterization in the Pediatric Population
Current Cardiology Reviews Synthesis, Chemistry and Utilities of Diaminoazoles with Special Reference to 3,5-diaminopyrazoles
Current Organic Synthesis MicroRNA: Novel Modulators of the Cholinergic Anti-Inflammatory Pathway
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Ghrelin Receptor Signaling: A Promising Therapeutic Target for Metabolic Syndrome and Cognitive Dysfunction
CNS & Neurological Disorders - Drug Targets